Patent Application
20080234323
The present invention describes novel forms of Rimonabant hydrochloride, processes for their preparation and pharmaceutical compositions containing them. The present invention also describes method of treatment of obesity, smoking cessation, overweight and related diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of the said novel polymorphs and pharmaceutical composition containing them. The present invention relates to the use of novel polymorphs of Rimonabant hydrochloride disclosed herein and pharmaceutical compositions containing them for the treatment of obesity, smoking cessation, overweight and related diseases.
Rimonabant is one of the potentially newer therapies discovered for the treatment of obesity, smoking cessation, overweight and related diseases, currently undergoing Phase-III clinical trials.
Rimonabant is 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)pyrazole-3-carboxamide, having structural formula I.
It is presently being developed by Sanofi as its hydrochloride salt, as a CB1 antagonist, as a potential treatment for obesity, smoking cessation, Alzheimer's disease, Parkinson's disease etc. This compound was first disclosed in EP 656354 and also in U.S. Pat. No. 5,624,941 which is hereby incorporated by reference in its entirety.
The therapeutic applications of Rimonabant has been described in U.S. Pat. No. 6,344,474, U.S. Pat. No. 6,642,258, WO 0158450, WO 0185092, WO 0318060, WO 0382256 etc. which are also incorporated in their entirety as reference.
WO 03040105 (Sanofi) and US 20050043356 discloses one new crystalline form of Rimonabant base designating it as Form II of the compound, which is also hereby incorporated as reference in its entirety.
U.S. Pat. No. 5,624,941 (Sanofi) discloses the HCl salt of Rimonabant having a melting point of 224° C. The method claimed in this patent allows the preparation of Rimonabant hydrochloride in crystalline form which will be called as Form 1.
However, the present inventors have found that the crystalline form of Rimonabant hydrochloride disclosed in the above mentioned application is difficult to purify, difficult to reproduce by the process described in U.S. Pat. No. 5,624,941. Hence, the present inventors felt the need to develop such forms, which are very stable, reproducible and easy to formulate. It has now been surprisingly found out that Rimonabant hydrochloride can exist in different polymorphic crystalline forms which differ from each other in their stability, in their physical properties, in their spectral characteristics and in their methods of preparation. Surprisingly, these new forms were found to be easy to purify, are easily reproducible and can be formulated easily. Moreover, it was found that the crystalline forms of the present invention were stable making them suitable for use as pharmaceutically acceptable products.
It is normally accepted that the amorphous form of any compound are less desirable due to obvious problems in formulating an amorphous solid. Moreover, such forms have the problem of stickiness due to moisture absorption, very high solubility and other associated problems. However, it was surprisingly found that one of the amorphous form of Rimonabant hydrochloride of the present invention was very stable over long term. The enhanced stability of the amorphous form of the present invention may be probably due to the presence of water molecule associated with the salt. Preliminary studies indicate that such amorphous form may be suitable for preparation of intravenous and/or injectable formulation of the drug, which will have significant therapeutic applications. Such novel formulations may be tried out for this drug looking at the type of diseases for which the drug is indicated. It has also been found surprisingly that one of the amorphous form of the present application can be used to obtain the different forms of Rimonabant hydrochloride in pure form.
The present invention thus discloses amorphous forms and three new crystalline forms of Rimonabant hydrochloride designated as Form II, Form III & Form IV respectively.
Accordingly, the present invention provides new crystalline forms of Rimonabant hydrochloride or mixture thereof.
In another embodiment of the present invention is provided novel amorphous forms of Rimonabant hydrochloride.
In a further embodiment is provided processes for the preparation of the novel forms of Rimonabant hydrochloride or mixture thereof.
Yet in another embodiment is provided pharmaceutical compositions comprising the said novel forms of Rimonabant hydrochloride.
In a still further embodiment is provided uses of the novel forms of Rimonabant hydrochloride or the treatment of obesity, Parkinson's disease, Alzheimer's disease, smoking cessation and other related diseases.
Rimonabant is (I) 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)pyrazole-3-carboxamide, having structural formula (I).
The present invention provides novel forms of Rimonabant hydrochloride as given below:
The novel forms of Rimonabant hydrochloride are characterized by unique XRD patterns which are different from the various forms reported in the above mentioned applications.
The present invention also discloses processes for the preparation of the said novel forms of Rimonabant hydrochloride and pharmaceutical compositions containing them and their use in medicine. The general processes for preparing the various novel forms of the present invention are provided below. It will be appreciated that a skilled person may modify/alter these processes suitably in an obvious manner and such obvious alternations/modifications are considered included within the scope of the present application.
The novel amorphous form of Rimonabant hydrochloride may be prepared by dissolving/contacting Rimonabant base in suitable solvents selected from (C1-C6) alcohols such as methanol, ethanol, propanol, n-butanol and the like, benzene, dichloromethane, dichloroethane, acetone, cyclohexane, dimethyl formamide, dimethyl acetamide, 1,4-dioxane, tetrahydrofuran or mixtures thereof and treating with dilute HCl, stirring the solution, filtering and controlled drying the residue to obtain amorphous form of Rimonabant hydrochloride, having XRD pattern as provided in
The amorphous form of Rimonabant hydrochloride was stirred in ethyl acetate, suitable ethers such as diethyl ether, methyl t-butyl ether (MTBE), diisopropyl ether and the like or mixtures thereof, filtered and subsequently removing the solvent from the solid obtained to get the novel crystalline form II of Rimonabant hydrochloride, m. p. −237-244° C. and having characteristic XRD pattern, as provided in
The amorphous form of Rimonabant hydrochloride was stirred in isopropanol, filtered and subsequently removing the solvent from the solid obtained to get the novel crystalline form III of Rimonabant hydrochloride, m. p. −240-245° C. and having characteristic XRD pattern as provided in
The amorphous form of Rimonabant hydrochloride was stirred in (C5-C12) alcohols such as pentanol, isopentanol, hexanol, heptanol, decanol, undecanol and the like, acetone or mixtures thereof, filtered and subsequently removing the solvent from the solid obtained to get the novel crystalline form IV of Rimonabant hydrochloride, m.p. 242-244° C. and having characteristic XRD pattern as provided in
The various pharmaceutical compositions and formulations of the novel forms of Rimonabant hydrochloride of the present invention can be prepared by processes well known. The dosage of the novel forms of Rimonabant hydrochloride of the present invention is selected according to the usage and may vary as per the requirement of the patient.
Pharmaceutical compositions of the present invention contains amorphous Rimonabant hydrochloride and new crystalline forms II, III and IV of Rimonabant hydrochloride, optionally in mixture with other form(s) or amorphous Rimonabant hydrochloride as active ingredients. Rimonabant hydrochloride forms II, III, IV and amorphous form obtained by the processes of the present invention are ideal for pharmaceutical composition in that they have the purity of at least about 90%, more preferably at least about 95% and most preferably at least about 99%. In addition to the active ingredient(s), the pharmaceutical composition of the present invention may contain one or more excipients. Excipients are added to the composition for preparing various dosage forms using the techniques and processes known.
The novel forms of Rimonabant hydrochloride of the present invention may be used for the treatment of obesity, Parkinson's disease, Alzheimer's disease, smoking cessation and other related diseases in a mammal including human.
The process described in the present invention is illustrated in the following examples which are provided for illustration only and should not be construed to limit the scope of the invention in any way.
Rimonabant base 5 g was dissolved in methanolic HCl solution till acidic pH, followed by addition of water and the reaction mixture was stirred at room temperature. The solvent was distilled off under reduced pressure to get a sticky solid mass. Methanol was added and again solvent was distilled off to get the desired solid. XRD pattern showed the amorphous form of the compound.
% water: 3-5% (different batches)
Rimonabant hydrochloride 5 g was dissolved in hot methanol at 40-50° C., to which was added crushed ice, the mass stirred for 20 to 40 minutes, scratched and filtered. The solid was washed with water and dried to obtain the salt. XRD pattern showed amorphous form of the compound.
% water: 3-5% (different batches)
1 g amorphous Rimonabant hydrochloride in partially hydrated form obtained as above was dried at 105-110° C. in a drier for about 4 to 5 hours to get the amorphous compound in anhydrous form.
5 g of amorphous Rimonabant hydrochloride was stirred in diethyl ether at 25-30° C. for about 20 to 24 hours, filtered and washed with diethyl ether and subsequently removing the solvent from the filtered solid to get the solid compound. m.p. 237-244° C.
5 g of amorphous Rimonabant hydrochloride was stirred in ethyl acetate at 25-30° C. for about 20 to 24 hours, filtered and washed with ethyl acetate and subsequently removing the solvent from the filtered solid to get the solid compound. m.p. 237-244° C.
5 g of amorphous Rimonabant hydrochloride was stirred in isopropyl alcohol at 25-30° C. for about 20 to 24 hours, filtered and washed with isopropyl alcohol and subsequently removing the solvent from the filtered solid to get the solid compound. m.p. 244-245° C.
5 g of amorphous Rimonabant hydrochloride was stirred in 1-pentanol at 25-30° C. for about 20 to 24 hours, filtered and washed with 1-pentanol and subsequently removing the solvent from the filtered solid to get the solid compound. m.p. 242-244° C.
5 g of amorphous Rimonabant hydrochloride was stirred in acetone at 25-30° C. for 20 to 24 hours, filtered and washed with acetone and subsequently removing the solvent from the residue to get the solid compound. m.p. 243-247° C.
1 g of amorphous Rimonabant hydrochloride was taken in ethyl acetate, heated on a water bath to 50-60° C. for 15-20 minutes and filtered. The solid was washed with anhydrous diethyl ether and dried to obtain 800 mg of the product, m.p. 218-220° C., % purity 99.72%.
Thus, the amorphous form of Rimonabant hydrochloride may be used to prepare the Form I of Rimonabant hydrochloride with very high purity.
The crystalline forms were found to be stable in 5 month stability studies carried out at 25° C. 60% RH as well as 40° C., 75% RH. No polymorphic changes were observed. The amorphous forms were found to be stable at 3 months at room temperature.
| Number | Date | Country | Kind |
|---|---|---|---|
| 15/MUM/2005 | Jan 2005 | IN | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/IN06/00006 | 1/6/2006 | WO | 00 | 4/28/2008 |
